company background image
6549

TaiwanJ Pharmaceuticals TPEX:6549 Stock Report

Last Price

NT$10.05

Market Cap

NT$755.0m

7D

0%

1Y

-24.4%

Updated

24 May, 2022

Data

Company Financials
6549 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6549 Stock Overview

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan.

TaiwanJ Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for TaiwanJ Pharmaceuticals
Historical stock prices
Current Share PriceNT$10.05
52 Week HighNT$15.00
52 Week LowNT$9.07
Beta0.83
1 Month Change-9.46%
3 Month Change-23.86%
1 Year Change-24.44%
3 Year Change-15.55%
5 Year Change-44.17%
Change since IPO-79.90%

Recent News & Updates

Apr 14
Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth

Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Dec 29
Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?

Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

6549TW BiotechsTW Market
7D0%0.5%1.5%
1Y-24.4%7.3%-0.7%

Return vs Industry: 6549 underperformed the TW Biotechs industry which returned 7.3% over the past year.

Return vs Market: 6549 underperformed the TW Market which returned -0.7% over the past year.

Price Volatility

Is 6549's price volatile compared to industry and market?
6549 volatility
6549 Average Weekly Movement4.5%
Biotechs Industry Average Movement5.2%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.2%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 6549 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 6549's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201114Rich Yuanhttps://www.taiwanj.com

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis.

TaiwanJ Pharmaceuticals Fundamentals Summary

How do TaiwanJ Pharmaceuticals's earnings and revenue compare to its market cap?
6549 fundamental statistics
Market CapNT$754.98m
Earnings (TTM)-NT$12.42m
Revenue (TTM)NT$22.06m

34.2x

P/S Ratio

-60.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6549 income statement (TTM)
RevenueNT$22.06m
Cost of RevenueNT$0
Gross ProfitNT$22.06m
Other ExpensesNT$34.48m
Earnings-NT$12.42m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin100.00%
Net Profit Margin-56.32%
Debt/Equity Ratio0%

How did 6549 perform over the long term?

See historical performance and comparison

Valuation

Is TaiwanJ Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


4.62x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6549 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW Biotechs industry average.

PE vs Market: 6549 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6549's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6549 is overvalued based on its Price-To-Book Ratio (4.6x) compared to the TW Biotechs industry average (3.8x).


Future Growth

How is TaiwanJ Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


143.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TaiwanJ Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has TaiwanJ Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


43.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6549 is currently unprofitable.

Growing Profit Margin: 6549 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6549 is unprofitable, but has reduced losses over the past 5 years at a rate of 43.8% per year.

Accelerating Growth: Unable to compare 6549's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6549 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).


Return on Equity

High ROE: 6549 has a negative Return on Equity (-7.6%), as it is currently unprofitable.


Financial Health

How is TaiwanJ Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6549's short term assets (NT$88.4M) exceed its short term liabilities (NT$6.9M).

Long Term Liabilities: 6549 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 6549 is debt free.

Reducing Debt: 6549 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6549 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6549 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 40.9% each year


Dividend

What is TaiwanJ Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6549's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6549's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6549's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6549's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6549 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Rich Yuan

3.92yrs

Tenure

Mr. Hung-Chang Yuan, also known as Rich, has been General Manager of TaiwanJ Pharmaceuticals Co., Ltd. since June 2018. Mr. Yuan served as Chief Financial Officer of TaiwanJ Pharmaceuticals Co., Ltd.since...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TaiwanJ Pharmaceuticals Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: TaiwanJ Pharmaceuticals Co., Ltd.
  • Ticker: 6549
  • Exchange: TPEX
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$754.976m
  • Shares outstanding: 75.12m
  • Website: https://www.taiwanj.com

Number of Employees


Location

  • TaiwanJ Pharmaceuticals Co., Ltd.
  • No.2 ShengYi Road
  • Room D207, Section-2
  • Zhubei
  • 30261
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.